Breaking News Instant updates and real-time market news.

ABBV

AbbVie

$84.27

-3.74 (-4.25%)

, DCPH

Deciphera

$22.62

0.4 (1.80%)

04:55
10/23/18
10/23
04:55
10/23/18
04:55

European Society for Medical Oncology (ESMO) to hold a conference

ESMO 2018 Congress to be held in Munich, Germany on October 19-23.

ABBV

AbbVie

$84.27

-3.74 (-4.25%)

DCPH

Deciphera

$22.62

0.4 (1.80%)

TSRO

Tesaro

$36.88

-4.93 (-11.79%)

IMGN

ImmunoGen

$6.23

-1.205 (-16.21%)

REGN

Regeneron

$388.16

-1.78 (-0.46%)

CRSP

Crispr Therapeutics

$35.43

-0.59 (-1.64%)

CLVS

Clovis

$21.09

-5.32 (-20.14%)

MRTX

Mirati Therapeutics

$34.01

-6.03 (-15.06%)

LOXO

Loxo Oncology

$161.90

1.89 (1.18%)

RHHBY

Roche

$0.00

(0.00%)

NCNA

NuCana

$17.85

-1.05 (-5.56%)

CRVS

Corvus Pharmaceuticals

$7.98

-0.03 (-0.37%)

NTGN

Neon Therapeutics

$7.60

-1.28 (-14.41%)

NKTR

Nektar

$39.97

-8.26 (-17.13%)

EXEL

Exelixis

$15.45

-0.82 (-5.04%)

AVEO

Aveo Pharmaceuticals

$2.14

-0.36 (-14.40%)

KURA

Kura Oncology

$11.63

-2.75 (-19.12%)

  • 24

    Oct

  • 25

    Oct

  • 26

    Oct

  • 28

    Oct

  • 30

    Oct

  • 01

    Nov

  • 01

    Nov

  • 02

    Nov

  • 02

    Nov

  • 06

    Nov

  • 07

    Nov

  • 10

    Nov

  • 26

    Nov

  • 27

    Nov

  • 24

    Dec

  • 14

    Jan

  • 28

    Apr

  • 13

    May

ABBV AbbVie
$84.27

-3.74 (-4.25%)

10/19/18
FBCO
10/19/18
NO CHANGE
Target $85
FBCO
Underperform
AbbVie's 'surprise' CFO change raises more questions, says Credit Suisse
After AbbVie announced this morning that CFO Bill Chase will retire in mid-2019 and be replaced by the current Controller Robert Michael, Credit Suisse analyst Vamil Divan said he was "surprised" by the news for several reasons. He does not recall recent commentary from the company suggesting a CFO transition was in the works; he does not believe the Street had been expecting a CFO transition; the change is clearly happening at a sensitive time, given the launch of biosimilar versions of Humira in Europe this week and increasing questions around the mid-to-long term growth outlook for Humira in the U.S.; and this news was disclosed in an 8-K with no accompanying press release, Divan noted. While comments reinforcing the company's views on its longer-term outlook are "not required" in this case, they would have made Divan feel more comfortable that this was a well-planned transition, he added. The analyst keeps an Underperform rating and $85 price target on AbbVie shares, which are down 1% to $88.88.
09/19/18
MSCO
09/19/18
NO CHANGE
MSCO
Equal Weight
Morgan Stanley says AbbVie market cap fell more than largest drug settlement
After AbbVie (ABBV) slid about 3% yesterday following a California Insurance Commissioner lawsuit alleging Humira kickbacks, Morgan Stanley analyst David Risinger noted its $4B loss in market cap was larger than GlaxoSmithKline's (GSK) previous $3B settlement for violations under the False Claims Act, which he called the biggest ever historical pharma settlement. While Commissioner Dave Jones claims imply that the potential fine for Abbvie could theoretically be more than $3B, Risinger also noted that the company told him it believes the allegations "are completely without merit." He maintains an Equal Weight rating and $100 price target on AbbVie shares.
10/02/18
PIPR
10/02/18
NO CHANGE
Target $100
PIPR
Neutral
AbbVie scripts for Humira relatively weak in Q3, says Piper Jaffray
Piper Jaffray analyst Christopher Raymond says new survey data from dermatologists and gastroenterologists indicate AbbVie's (ABBV) Humira is losing share faster in psoriasis and inflammatory bowel disease than in rheumatoid arthritis. In that management has called out psoriasis as a key driver of growth, the survey feedback may help explain Humira's relatively weak script trends for Q3, Raymond tells investors in a research note. The analyst believes dermatologists are embracing newer biologics such as Johnson & Johnson's (JNJ) Tremfya while gastroenterologists favor Takeda's Entyvio and increasingly Pfizer's (PFE) Xeljanz. Raymond remains cautious on shares of AbbVie ahead of European biosimilar erosion he expects to start this month. He keeps a Neutral rating on the stock with a $100 price target.
10/22/18
RHCO
10/22/18
NO CHANGE
Target $135
RHCO
Buy
AbbVie price target lowered to $135 from $157 at SunTrust
SunTrust analyst John Boris lowered his price target on AbbVie to $135 after his discussions with its management about the challenges coming from "Humira biosimilar discounts" in the E.U. The analyst notes that he is also lowering his FY19 revenue forecasts to $33.9B from $34.5B to reflect his updated lower HCV global market model and lower Mavyret sales from lower volumes. Boris also keeps his Buy rating on AbbVie longer term, citing potential benefits from the Imbruvica/Venclexta uptake/label expansion and any incremental M&A under incoming CFO Rob Michael.
DCPH Deciphera
$22.62

0.4 (1.80%)

10/19/18
PIPR
10/19/18
NO CHANGE
Target $50
PIPR
Overweight
Piper remains 'aggressive' buyer of Deciphera after 'derisking' data
Piper Jaffray analyst Christopher Raymond says he remains an "aggressive" buyer of Deciphera Pharmaceuticals and that the shares should recover this morning following the company's DCC-2618 gastrointestinal stromal tumors data presentation at the European Society of Medical Oncology meeting. With the backdrop of some investor concern that the data would bring an equivocal comp for DCC-2618 to Sutent, initial durability compares well as the ~9.7 month progression free survival in second-line GIST appears "decisively ahead" of Sutent's 6.1 months, "derisking" the Phase 3 head-to-head trial, Raymond tells investors in a research note. The analyst keeps an Overweight rating on Deciphera with a $50 price target.
09/19/18
PIPR
09/19/18
NO CHANGE
Target $50
PIPR
Overweight
Piper recommends Deciphera into systemic mastocytosis data
Piper Jaffray analyst Christopher Raymond keeps an Overweight rating on shares of Deciphera Pharmaceuticals (DCPH) with a $50 price target following a deep dive into the systemic mastocytosis treatment space and the potential for DCC-2618 to play a meaningful role in the disease. The analyst continues to recommend purchase of Deciphera into the systemic mastocytosis data for DCC-2618 early next year. Given what's been presented before between Novartis' (NVS) midostaurin and Blueprint Medicines' (BPMC) avapritinib, Raymond thinks an overall response rate of greater than 50% with a continued clean safety profile should be considered a win for DCC-2618. He models for DCC-2618 systemic mastocytosis revenue of $44M, $151M, and $290M for 2023 through 2025, respectively. The analyst remains a buyer of Deciphera shares into the Q1 of 2019 data.
09/17/18
GUGG
09/17/18
INITIATION
GUGG
Guggenheim calls Array, Deciphera, ImmunoGen top biotech picks
Guggenheim initiated coverage of the biotechnology sector, initiating and assuming coverage of 17 biotechnology stocks, and saying it is bullish on the sector longer term and expects continued growth. The firm's coverage focuses on the oncology therapeutic category, with Guggenheim calling Array Biopharma (ARRY), Deciphera Pharmaceuticals (DCPH), and ImmunoGen (IMGN), which all have key catalysts coming in the first half or 2019, its top picks.
09/24/18
LEER
09/24/18
INITIATION
Target $28
LEER
Underperform
Deciphera initiated with an Underperform at Leerink
Leerink analyst Andrew Berens started Deciphera Pharmaceuticals with an Underperform rating and $28 price target.
TSRO Tesaro
$36.88

-4.93 (-11.79%)

09/24/18
LEER
09/24/18
INITIATION
Target $48
LEER
Outperform
Tesaro initiated with an Outperform at Leerink
Leerink analyst Andrew Berens started Tesaro with an Outperform rating and $48 price target.
10/10/18
PIPR
10/10/18
NO CHANGE
Target $35
PIPR
Neutral
Tesaro raised Zejula 90-count capsule bottle price by 5%, says Piper Jaffray
According to Wolters Kluwer Health, Tesaro, effective today, took a 5% price increase on Zejula's 90-count capsule bottle, Piper Jaffray analyst Christopher Raymond tells investors in a research note. The analyst points out that in July, in the midst of a down-dosing effort aimed at reducing adverse events, management launched a 30-count capsule bottle at a 24% premium. Today's increase narrows that gap to 18%, and to the extent that physicians continue prescribing the 90-count capsule bottle, provides more confidence in Zejula's 2018 numbers, Raymond writes. He reiterates a Neutral rating on Tesaro shares with a $35 price target.
10/22/18
CANT
10/22/18
NO CHANGE
Target $68
CANT
Overweight
Tesaro price target raised to $68 from $57 at Cantor Fitzgerald
Cantor Fitzgerald analyst Alethia Young raised her price target for Tesaro (TSRO) to $68 saying AstraZeneca's (AZN) presented the Solo1 study using olaparib as a first-line treatment for BRCA ovarian cancer patients is positive for Tesaro's first-line study Prima study, with data expected in the second half of 2019. AstraZeneca's data clearly support broad use in first-line "at least" for BRCA ovarian cancer patients, which is positive for the PARP inhibitor class, Young tells investors in a research note. The analyst increased PARP inhibitor penetration in the BRCA patient at peak to 75% from 65% and reiterates an Overweight rating on Tesaro.
10/01/18
CANT
10/01/18
INITIATION
Target $57
CANT
Overweight
Tesaro initiated with an Overweight at Cantor Fitzgerald
Cantor Fitzgerald analyst Alethia Young started Tesaro with an Overweight rating and $57 price target.
IMGN ImmunoGen
$6.23

-1.205 (-16.21%)

07/30/18
HCWC
07/30/18
NO CHANGE
Target $18
HCWC
Buy
ImmunoGen remains a top SMID-cap idea at H.C. Wainwright
H.C. Wainwright analyst Debjit Chattopadhyay says ImmunoGen's mirvetuximab soravtansine, or IMGN853, "continues to chug along, almost unnoticed, especially at current levels." ImmunoGen remains well positioned to "significantly expand" its commercial positioning with multiple pivotal programs positioned to move IMGN853 into earlier lines of therapy, Chattopadhyay tells investors in a research note. The analyst awaits the topline readout from the Forward I program during the first half of 2018 and notes that additional data from IMGN853 in combination with Keytruda are expected during the second half of 2018. He rates ImmunoGen as one of his top SMID-cap ideas heading into the readout of the Forward I. The analyst reiterates a Buy rating on the shares with an $18 price target.
09/06/18
PIPR
09/06/18
INITIATION
Target $15
PIPR
Overweight
ImmunoGen initiated with an Overweight at Piper Jaffray
Piper Jaffray analyst Joseph Catanzaro started ImmunoGen with an Overweight rating and $15 price target. The analyst says the company's wholly-owned oncology asset is nearing a pivotal readout.
09/17/18
GUGG
09/17/18
INITIATION
Target $19
GUGG
Buy
ImmunoGen initiated with a Buy at Guggenheim
Target $19.
REGN Regeneron
$388.16

-1.78 (-0.46%)

10/22/18
PIPR
10/22/18
NO CHANGE
Target $450
PIPR
Overweight
Regeneron asthma label for Dupixent broad as hoped, says Piper Jaffray
Piper Jaffray analyst Christopher Raymond says that while Regeneron Pharmaceuticals' asthma label for Dupixent does not broadly cover patients regardless of eosinophilic phenotype as he had anticipated, it does cover oral corticosteroid dependent patients regardless of eosinophilic phenotype, which essentially matches his modeling. Moreover, the analyst notes that the label covers all patients 12 and older, and both moderate and severe disease. As such, he sees the label as broad, "but not necessarily as anticipated." The analyst is making no change to his numbers based on the label and keeps an Overweight rating on Regeneron with a $450 price target.
10/17/18
JEFF
10/17/18
NO CHANGE
Target $31
JEFF
Buy
Jefferies still sees 'major' opportunity for Optinose after Dupixent data
Optinose (OPTN) shares underperformed yesterday following the positive Phase 3 results for Sanofi (SNY) and Regeneron's (REGN) Dupixent in treating patients with chronic rhinosinusitis with nasal polyps, Jefferies analyst David Steinberg tells investors in a research note titled "Biologics Competitor as Expected; Real World Pricing Issues Likely to Limit Us." The analyst says that while Dupixent demonstrated strong efficacy, clinicians he's spoken with believe that the "massive" pricing disparity versus nasal steroids will likely result in payer "step edits" that could limit widespread adoption of the "expensive" biologics currently under development. Further, Dupixent's head-to-head comparison with Optinose's Xhance's "strong" efficacy profile is difficult, the analyst adds. Steinberg still sees a "major" long-term opportunity for Xhance and keeps a Buy rating on Optinose with a $31 price target.
10/22/18
CANT
10/22/18
NO CHANGE
Target $441
CANT
Neutral
Regeneron price target raised to $441 from $419 at Cantor Fitzgerald
Cantor Fitzgerald analyst Alethia Young raised her price target for Regeneron Pharmaceuticals to $441 citing Dupixent's label in asthma, which she thinks is broad. The analyst believes the shares could trade up 5% on the label but she keeps a Neutral rating on the name. Dupixent expectations are high already, Young tells investors in a research note.
10/16/18
LEER
10/16/18
NO CHANGE
LEER
Outperform
Regeneron data won't derail Intersect ENT's Sinuva, says Leerink
Leerink analyst Richard Newitter attributes the underperformance today in shares of Intersect ENT (XENT) to Regeneron's (REGN) positive Phase 3 Dupixent data for chronic rhinosinusitis with nasal polyps. The Dupixent readout had always represented a potential headline risk for Intersect ENT during Q4, Newitter tells investors in a research note. The analyst, however, thinks it's better to get the headline out of the way before a J-code decision in early November. Further, based on physician feedback around monoclonal antibodies, Newitter does not get the sense that these therapies will "necessarily derail" adoption of Intersect ENT's Sinuva or its total addressable market. The analyst continues to believe in-line Q3 results will be a "win" for Intersect ENT and he keeps an Outperform rating on the shares. The stock in afternoon trading is down 68c to $29.24.
CRSP Crispr Therapeutics
$35.43

-0.59 (-1.64%)

10/15/18
PIPR
10/15/18
NO CHANGE
PIPR
Piper lists names to own in Biopharma after recent selloff
Piper Jaffray's biopharma analyst team highlighted names to own in the Biopharma sector following the recent selloff of the broader market. The firm's ideas include: Adamas Pharmaceuticals (ADMS), Agios Pharmaceuticals (AGIO), Agios Pharmaceuticals (ALNY), Alexion (ALXN), Bluebird Bio (BLUE), BioMarin (BMRN), CymaBay (CBAY), Crispr Therapeutics (CRSP), Global Blood Therapeutics (GBT), Horizon Pharma (HZNP), Jazz Pharmaceuticals (JAZZ), Ocular Therapeutix (OCUL), Rigel Pharmaceuticals (RIGL) and Xencor (XNCR).
10/10/18
10/10/18
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Take-Two (TTWO) initiated with an Outperform at Bernstein. 2. Shake Shack (SHAK) initiated with a Hold at Stifel. 3. Nu Skin (NUS) initiated with a Buy at DA Davidson. 4. Micron (MU) initiated with a Neutral at Piper Jaffray. 5. Crispr Therapeutics (CRSP) initiated with an Outperform at Wells Fargo. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
10/10/18
WELS
10/10/18
INITIATION
Target $65
WELS
Outperform
Crispr Therapeutics initiated with an Outperform at Wells Fargo
Wells Fargo analyst Jim Birchenough started Crispr Therapeutics with an Outperform rating and $65 price target. The analyst cited the company's "highly leverageable" gene editing platform, "substantially de-risked" lead program in ex-vivo gene editing for beta thalassemia and sickle cell disease, a broad pipeline of both ex vivo and in vivo gene-editing opportunities, and strong collaborations balancing wholly owned programs to optimize future value creation.
10/09/18
GUGG
10/09/18
INITIATION
GUGG
Neutral
Crispr Therapeutics assumed with a Neutral at Guggenheim
Guggenheim analyst Whitney Ijem assumed coverage of Crispr Therapeutics with a Neutral rating, saying the potential of Crispr's "highly innovative platform and diversified approach" is already reflected at current levels.
CLVS Clovis
$21.09

-5.32 (-20.14%)

10/19/18
PIPR
10/19/18
NO CHANGE
PIPR
Neutral
Clovis data 'solid,' but others likely to follow, says Piper Jaffray
Piper Jaffray analyst Joseph Catanzaro believes Clovis Oncology reported "solid" initial data from the Triton2 study evaluating Rubraca in HRD+ metastatic castrate resistant prostate cancer patients. In the subset of BRCA+ patients, Rubraca reported a 44% objective response rate and 51.1% confirmed prostate specific antigen response rate, Catanzaro tells investors in a research note. The analyst says that while this is "definitely a positive outcome" for Rubraca, he expects "this opportunity to become very competitive in the near term." He feels Rubraca is likely not the last PARP to show these response rates and keeps a Neutral rating on Clovis shares.
10/02/18
JPMS
10/02/18
NO CHANGE
JPMS
Overweight
JPMorgan increasingly confident in Clovis Oncology's rucaparib
JPMorgan analyst Cory Kasimov is encouraged by Clovis Oncology's announcement this morning that rucaparib received breakthrough designation from the FDA for the third line treatment of patients with BRCA mutated metastatic castrate-resistant prostate cancer on the basis of data from the Triton-2 study. The analyst says the news further increases his confidence in the potential for rucaparib to produce response rates that are meaningfully better than currently available options. His model implies $9 per share for prostate, assuming a 55% probability of success and $450M in peak unadjusted sales. Kasimov keeps an Overweight rating on Clovis, which is up 11%, or $3.33, to $32.47 in morning trading.
10/19/18
RHCO
10/19/18
NO CHANGE
Target $90
RHCO
Buy
SunTrust impressed by prostate cancer data from Clovis
The initial Triton2 data this morning from Clovis Oncology show an "impressive" objective response rate at 44%, which is at the higher end of expectations, SunTrust analyst Peter Lawson tells investors in a research note. The analyst notes the 44% is above his previewed ORR of greater than 20% and that management previously mentioned that a 20%-25% rate would be impressive. Lawson finds the supportive confirmed prostate specific antigen response rate of 51% as impressive also. He reiterates a Buy rating on Clovis shares with a $90 price target. The stock in morning trading is down 2%, or 67c, to $29.29.
10/18/18
PIPR
10/18/18
INITIATION
Target $33
PIPR
Neutral
Clovis assumed with a Neutral at Piper Jaffray
Piper Jaffray analyst Joseph Catanzaro assumed coverage of Clovis Oncology with a Neutral rating and $33 price target. The analyst believes the shares are fairly valued based on Rubraca's long-term potential across the ovarian cancer treatment landscape. He also has concerns with near- and long-term consensus estimates for the drug.
MRTX Mirati Therapeutics
$34.01

-6.03 (-15.06%)

09/27/18
COWN
09/27/18
NO CHANGE
COWN
Outperform
Mirati Therapeutics weakness a buying opportunity, says Cowen
Cowen analyst Chris Sibutani said he sees the pullback in Mirati Therapeutics shares as an attractive buying opportunity and reiterates his Outperform rating on the stock. There was never a reason to expect that Mirati's data was under consideration for a late-breaking abstract presentation at ESMO, Sibutani tells investors. He expects management to share their plans for the sitravatinib + nivolumab pivotal study program at the ESMO meeting after data is presented on Monday, October 22. The analyst maintains an Outperform rating on Mirati shares.
09/17/18
GUGG
09/17/18
INITIATION
Target $54
GUGG
Neutral
Mirati Therapeutics initiated with a Neutral at Guggenheim
Target $54.
07/20/18
HCWC
07/20/18
NO CHANGE
Target $63
HCWC
Buy
Mirati Therapeutics price target raised to $63 from $42 at H.C. Wainwright
H.C. Wainwright analyst Edward White raised his price target for Mirati Therapeutics to $63 to reflect a higher probability of success for sitravatinib. The analyst now applies a 45% probability of success for sitravatinib monotherapy and projects revenues of $407M, $448M and $179M for sitravatinib in combination with checkpoint therapy, sitravatinib as a single agent and mocetinostat, respectively, in 2027. He keeps a Buy rating on Mirati Therapeutics.
07/09/18
OPCO
07/09/18
NO CHANGE
Target $62
OPCO
Outperform
Mirati Therapeutics price target raised to $62 from $35 at Oppenheimer
Oppenheimer analyst Leah Rush Cann raised her price target for Mirati Therapeutics to $62 from $35 to account for an increased average forward price-to-sales multiple of the biotechnology sector. The analyst reiterates an Outperform rating on the shares.
LOXO Loxo Oncology
$161.90

1.89 (1.18%)

10/07/18
PIPR
10/07/18
NO CHANGE
Target $200
PIPR
Overweight
Loxo Oncology's 292 remains on top after RET data updates, says Piper Jaffray
Piper Jaffray analyst Tyler Van Buren reiterates an Overweight rating and $200 price target for Loxo Oncology (LOXO) after the company provided an update of the thyroid patients in the Phase I/II study of LOXO-292. The analyst highlights that in the largest patient population the response rate increased from 45% to 59% with three additional patients responding between 9 and 12 months. Blueprint Medicines' (BPMC) competing BLU-667 reported a 49% ORR in a similar patient population and recall that adverse events of hypertension are still a concern, he notes. Van Buren believes that the 667's safety profile could continue to look worse as it continues to administer the drug to patients at higher doses and that treatment discontinuations could increase. Overall, the analyst believes Loxo's 292 appears to be the superior RET inhibitor in development, both in terms of efficacy and safety and could easily become a $1B+ drug.
10/08/18
10/08/18
UPGRADE
Target $190

Outperform
Loxo Oncology upgraded to Outperform on LOXO-292 update at IFS Securities
As previously reported, IFS Securities analyst David Bouchey upgraded Loxo Oncology to Outperform from Market Perform, with $190 price target, after the company reported updated results from its Phase I/II trial for LOXO-292. The analyst believes the response rates for LOXO-292 continue to look "very strong," the safety data is "excellent" and early results show that these responses appear durable. So far, the drug has outperformed expectations, he adds.
10/22/18
PIPR
10/22/18
NO CHANGE
Target $200
PIPR
Overweight
Loxo 'highly likely' to win FDA approval next month, says Piper Jaffray
Loxo Oncology (LOXO) this weekend reported updated durability data for the original 55 TRK fusion patients treated with larotrectinib plus initial efficacy data from 54 newly-evaluable patients, Piper Jaffray analyst Tyler Van Buren tells investors in a research note. He points out that the new patient dataset displayed a nearly identical response rate and that duration is tracking similarly with three quarters of patients maintaining a response out to a year. The updated larotrectinib data compare well to Roche's (RHHBY) competing entrectinib and makes the drug "highly likely" to be approved on or by the November 26 FDA action date, contends Van Buren. He reiterates an Overweight rating on Loxo Oncology with a $200 price target.
10/08/18
IFSG
10/08/18
UPGRADE
IFSG
Outperform
Loxo Oncology upgraded to Outperform from Market Perform at IFS Securities
RHHBY Roche
$0.00

(0.00%)

10/16/18
WELS
10/16/18
NO CHANGE
WELS
Drug price in ads not impactful, may cause confusion, says Wells Fargo
Wells Fargo analyst David Maris acknowledges that the U.S. Department of Health and Human Services' proposal to include drug prices in advertisements has a "noble goal" of making drugs more affordable and keeping patients well informed. However, given how different list prices are relative to out of pocket costs, "one must ask if this is increasing transparency or likely going to lead to more confusion," he contends. The analyst also believes that the unintended consequence could be worse care, while noting that the drug price information will likely fall into the category of the side effect information in drug ads currently, tuned out by many and will have no material impact. While he supports the idea of increased transparency, Maris wonders whether the potential benefit is not outweighed by the potential negative for the most vulnerable. Publicly traded companies in the space include AstraZeneca (AZN), Bristol-Myers (BMY), Eli Lilly (LLY), GlaxoSmithKline (GSK), Johnson & Johnson (JNJ), Merck (MRK), Novartis (NVS), Pfizer (PFE), Roche (RHHBY) and Sanofi (SNY).
10/22/18
HCWC
10/22/18
NO CHANGE
Target $54
HCWC
Neutral
Roche data should concern Nektar bulls, says H.C. Wainwright
H.C. Wainwright analyst Debjit Chattopadhyay believes Roche's (RHHBY) preliminary data of RO6875281, a fibroblast activation protein targeted interleukin-2 variant, should concern the bulls of Nektar Therapeutics (NKTR). The 11% and 20% overall response rate for single agent RO6875281 in squamous cell head and neck cancer and melanoma is compelling, Chattopadhyay tells investors in a research note. Nektar's NKTR-214 had no monotherapy activity, and the early promise in combination with Opdivo "has faded potentially due to its limited PK profile," the analyst adds. In addition, Chattopadhyay believes the monotherapy activity with pegilodecakin, a pegylated IL-10 being developed by Eli Lily (LLY), further complicates the competitive landscape for NKTR-214. He believes the second generation of "not alpha" IL-2, which is poised to enter the clinic during 2019, could further "upend" NKTR-214 and might compel Nektar's partner Bristol-Myers Squibb (BMY) to "re-evaluate the aggressive development strategy that was outlined earlier this year." The analyst keeps a Neutral rating on Nektar with a $54 price target.
10/15/18
RBCM
10/15/18
NO CHANGE
RBCM
Sector Perform
Roche breast cancer data could pressure Puma shares, says RBC Capital
RBC Capital analyst Kennen MacKay thinks the data presented this morning by Roche's (RHHBY) Genentech could pressure shares of Puma Biotechnology (PBYI) today. Genentech announced the Phase III Katherine study met its primary endpoint, showing Kadcyla as a single agent reduced the risk of disease recurrence or death compared to Herceptin as an adjuvant treatment in people with HER2-positive early breast cancer who have residual disease present following neoadjuvant treatment. Kadcyla's ultimate entry into the HER2-positive adjuvant setting could complicate the positioning of Puma's Nerlynx, MacKay tells investors in a research note. He keeps a Sector Perform rating on shares of Puma, which are down 4%, or $1.55, to $41.14 in morning trading.
NCNA NuCana
$17.85

-1.05 (-5.56%)

10/21/18
PIPR
10/21/18
NO CHANGE
Target $36
PIPR
Overweight
NuCana updated Phase Ib data positive for acelarin in biliary cancer, says Piper Jaffray
Piper Jaffray analyst Joseph Catanzaro notes that NuCana presented updated Phase Ib data for Acelarin plus cisplatin in 1st-line advanced BTC at ESMO this weekend. An ORR of 50% in 14 patients is consistent with the abstract and continues to suggest a near doubling of standard of care, he adds, highlighting that tumor reductions appear to be durable out to the 36-week assessment and the safety profile is unremarkable compared to gem/cis. The analyst maintains his positive outlook for the planned Phase III trial and the opportunity to establish a new standard of care for this sizable patient population. Catanzaro reiterates an Overweight rating and $36 price target on the shares.
10/18/18
PIPR
10/18/18
INITIATION
Target $36
PIPR
Overweight
NuCana initiated with an Overweight at Piper Jaffray
Piper Jaffray analyst Joseph Catanzaro started NuCana with an Overweight rating and $36 price target, stating that data for its lead product, Acelarin, have "strongly" pointed towards platform validation. He sees an opportunity for the drug in platinum-resistant ovarian cancer and sees the potential for it to "establish a new frontline standard of care in biliary tract cancer," Catanzaro tells investors.
10/23/17
WBLR
10/23/17
INITIATION
WBLR
Outperform
NuCana initiated with an Outperform at William Blair
William Blair analyst Y. Katherine Xu started NuCana with an Outperform rating saying her probability-adjusted net present value model derives a fair value of $35 per share at the end of 2018 just based on the company's lead two assets. The analyst forecasts global peak sales of Acelarin in the first four indications, platinum-resistant ovarian cancer, platinum-sensitive ovarian cancer, biliary cancer, and pancreatic cancer-at GBP 800M with 40%-60% probabilities of success. She estimates NUC-3373 to generate peak sales of GBP 960M in the first two indications, advanced colorectal and breast cancers, with a 20% probability of success.
10/23/17
SBSH
10/23/17
INITIATION
Target $23
SBSH
Buy
NuCana initiated with a Buy at Citi
Citi analyst Yigal Nochomovitz started NuCana with a Buy rating and $23 price target. The company's technology platform produces "much-improved versions of decades-old chemo drugs, with minimal innovation risk," the analyst contends.
CRVS Corvus Pharmaceuticals
$7.98

-0.03 (-0.37%)

08/15/18
08/15/18
UPGRADE
Target $15

Outperform
Corvus Pharmaceuticals upgraded to Outperform at Credit Suisse
As previously reported, Credit Suisse analyst Michael Morabito upgraded Corvus Pharmaceuticals to Outperform from Neutral and raised the stock's price target to $15 from $11 after assuming coverage of the name. The analyst believes the company's lead product, CPI-444, has a clear lead in the clinic compared to competitors, and looks like a compelling treatment for PD-1 refractory patients, a growing market with PD-1 therapy being used increasingly in first-line settings.
08/15/18
FBCO
08/15/18
UPGRADE
FBCO
Outperform
Corvus Pharmaceuticals upgraded to Outperform from Neutral at Credit Suisse
06/05/18
JEFF
06/05/18
INITIATION
Target $17
JEFF
Buy
Corvus Pharmaceuticals initiated with a Buy at Jefferies
Jefferies analyst Biren Amin started Corvus Pharmaceuticals with a Buy rating and $17 price target. The analyst views CPI-444 as a potentially interesting immuno-oncology asset in non-small cell lung cancer and renal cell carcinoma.
NTGN Neon Therapeutics
$7.60

-1.28 (-14.41%)

07/23/18
MSCO
07/23/18
INITIATION
Target $23
MSCO
Overweight
Neon Therapeutics initiated with an Overweight at Morgan Stanley
Morgan Stanley analyst Matthew Harrison initiated Neon Therapeutics with an Overweight rating and $23 price target, as he views neoantigens as a relevant target that could improve the efficacy of current checkpoint inhibitors and believes initial data demonstrates an impact on the tumor. He sees 2019 as a pivotal year for Neon and expects followup from the initial data to drive outperformance, Harrison tells investors.
07/23/18
OPCO
07/23/18
INITIATION
Target $20
OPCO
Outperform
Neon Therapeutics initiated with an Outperform at Oppenheimer
Oppenheimer analyst Leah Rush Cann started Neon Therapeutics with an Outperform rating and $20 price target. The analyst estimates that Neon Therapeutics will first have product revenue in 2024 resulting in total revenue that year of $676.8M, potentially growing to $3.67B in 2025, if NEO-PV-01 is successful in currently planned indications.
07/23/18
BOFA
07/23/18
INITIATION
Target $18
BOFA
Buy
Neon Therapeutics initiated with a Buy at BofA/Merrill
BofA/Merrill analyst Ying Huang initiated Neon Therapeutics with a Buy and $18 price target. Huang sees a large market opportunity for Neon's personalized and "off-the-shelf" anti-cancer therapies, but notes theses therapies are in their infancy.
10/01/18
LTCO
10/01/18
INITIATION
Target $20
LTCO
Buy
Neon Therapeutics initiated with a Buy at Ladenburg
Ladenburg Thalmann analyst Kevin DeGeeter started Neon Therapeutics with a Buy rating and $20 price target. The analyst believes NEO-PV-01 "enjoys a powerful first mover advantage" in neoantigen therapies for improving both the depth and breadth of response of checkpoint inhibitors.
NKTR Nektar
$39.97

-8.26 (-17.13%)

07/31/18
HCWC
07/31/18
NO CHANGE
Target $54
HCWC
Neutral
Nektar approval for NKTR-181 likely priced in, says H.C. Wainwright
H.C. Wainwright analyst Debjit Chattopadhyay said he expects approval and a potential Class 3 scheduling or better for NKTR-181 by its PDUFA action date of May 29, 2019, but he also believes this is already priced into the stock at current levels. The future of Nektar remains leveraged to NKTR-214 and he expects the stock to be range-bound in the near-term given there is no interim updates on 214 expected until a meeting in November. An ORR above 60% would be a prerequisite for both melanoma and RCC for 214 to have "a clear shot at a Phase 3 win in the frontline I/O naive setting," but this is not a given based on the ASCO update, Chattopadhyay tells investors. He keeps a Neutral rating on Nektar shares.
08/08/18
PIPR
08/08/18
NO CHANGE
Target $125
PIPR
Overweight
Nektar offered more 'granularity' on PIVOT data timing, says Piper Jaffray
Piper Jaffray analyst Tyler Van Buren kept his Overweight rating and $125 price target on Nektar after its Q2 earnings beat, saying the management has also offered more detail on the company's data release plans. The analyst sees the 1L melanoma cohort readout coming before the end of 2018, followed by RCC and bladder cancer data likely in the first half of 2019 and other tumor types later next year. Van Buren adds that these disclosures should hopefully add to the company's understanding about the efficacy of 214+nivo combination therapy.
08/09/18
MZHO
08/09/18
NO CHANGE
Target $103
MZHO
Buy
Nektar to report additional data in coming months, says Mizuho
Mizuho analyst Difei Yang reiterates a Buy rating on Nektar Therapeutics with a $103 price target following last night's Q2 results. Data readouts of NKTR-214 remain the main catalyst for the shares, Yang tells investors in a research note. She points out that management expects to present data at a number of conferences in the coming months, including melanoma data at the Society for Immunotherapy of Cancer on November 7-11. While details on additional data in other indications "were sparse," data should be announced over the coming six-to-eight months, Yang contends.
EXEL Exelixis
$15.45

-0.82 (-5.04%)

10/08/18
PIPR
10/08/18
NO CHANGE
PIPR
Piper Jaffray optimistic on Exelixis' Cabometyx
Piper Jaffray analyst Edward Tenthoff reiterated an Overweight rating and $29 price target on Exelixis. The analyst noted that Exelixis initiated a Phase III trial of Cabometyx in radioiodine-refractory differentiated thyroid cancer, or DTC. He is looking for continued Cabometyx adoption in first and second-line renal cell carcinoma with sales of $572M this year, and sees Cabometyx approval in 2nd-line liver cancer by the January 14 PDUFA date, which will help drive sales to $873M in 2019.
09/17/18
GUGG
09/17/18
INITIATION
Target $27
GUGG
Buy
Exelixis initiated with a Buy at Guggenheim
Guggenheim initiated Exelixis with a Buy and $27 price target.
09/17/18
GUGG
09/17/18
INITIATION
Target $27
GUGG
Buy
Exelixis initiated with a Buy at Guggenheim
Target $27.
09/21/18
PIPR
09/21/18
NO CHANGE
Target $29
PIPR
Overweight
Piper Jaffray reiterates Overweight rating on Exelixis after CHMP decision
After Ipsen (IPSEY) announced a positive CHMP decision for Cabometyx as a monotherapy for the treatment of hepatocellular carcinoma, Piper Jaffray analyst Edward Tenthoff noted that Exelixis (EXEL) is eligible for tiered royalties of 22-26% after $100M in sales of the drug in Europe. He expects final EMA approval in coming months and also expects the FDA to approve Cabometyx in liver cancer by the January 14 PDUFA date, Tenthoff tells investors. He reiterated an Overweight rating and $29 price target on Exelixis shares.
AVEO Aveo Pharmaceuticals
$2.14

-0.36 (-14.40%)

08/16/18
08/16/18
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Post Holdings (POST) initiated with an Overweight at Piper Jaffray. 2. Stryker (SYK) initiated with a Buy at BTIG. 3. Aveo Pharmaceuticals (AVEO) initiated with a Buy at H.C. Wainwright. 4. Uxin (UXIN) initiated with a Buy at Goldman Sachs. 5. AcelRx (ACRX) initiated with a Buy at Ladenburg. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
08/16/18
HCWC
08/16/18
INITIATION
Target $6.5
HCWC
Buy
Aveo Pharmaceuticals initiated with a Buy at H.C. Wainwright
H.C. Wainwright analyst Swayampakula Ramakanth initiated Aveo Pharmaceuticals (AVEO) with a Buy rating and $6.50 price target, citing the view that tivozanib offers potentially the "best-in-class" safety profile when compared to leading TKIs on the market, such as Pfizer's (PFE) Sutent and Bayer's (BAYRY) Nexavar. Ramakanth projects tivozanib to reach the U.S. market in 2020 and achieve risk-adjusted revenues of $651M by 2030.
10/22/18
PIPR
10/22/18
NO CHANGE
Target $5
PIPR
Overweight
TiNivo data competitively position Aveo Pharmaceuticals, says Piper Jaffray
Piper Jaffray analyst Edward Tenthoff believes the data for tivozanib combined with Opdivo to treat metastatic renal cell carcinoma presented at the ESMO meeting competitively position Aveo Pharmaceuticals as the treatment landscape for front-line RCC moves to I-O and TKI combinations. An ORR of 56% and DCR of 96% represent "promising early activity," said Tenthoff., who reiterates his Overweight rating and $5 target on Aveo shares.
10/01/18
PIPR
10/01/18
NO CHANGE
Target $5
PIPR
Overweight
Piper remains confident in Aveo reporting positive TIVO-3 data
After an Independent Steering Committee recommended the initiation of top-line analysis of Aveo Pharmaceuticals' Phase 3 TIVO-3 trial of tivozanib in third-line renal cell carcinoma, Piper Jaffray analyst Edward Tenthoff noted that the lower than expected event rate of 242 events "minimally reduces" powering of the trial to 88% from the originally planned for 90%, but he remains confident in positive top-line TIVO-3 data being reported in about 6 weeks. Tenthoff reiterates his Overweight rating and $5 price target on Aveo shares.
KURA Kura Oncology
$11.63

-2.75 (-19.12%)

07/09/18
OPCO
07/09/18
NO CHANGE
Target $35
OPCO
Outperform
Kura Oncology price target raised to $35 from $27 at Oppenheimer
Oppenheimer analyst Leah Rush Cann raised her price target for Kura Oncology to $35 from $27, citing an increased average forward price-to-sales multiple of the biotechnology sector. The analyst reiterates an Outperform rating on the shares.
10/22/18
HCWC
10/22/18
NO CHANGE
Target $31
HCWC
Buy
H.C. Wainwright 'very encouraged' by Kura data, reiterates $31 price target
Kura Oncology this morning announced a positive outcome on its lead therapeutic candidate, tipifarnib, in Phase 2 clinical trial addressing the role of the drug in HRAS positive squamous cell carcinomas, H.C. Wainwright analyst Joseph Pantginis tells investors in a research note. The analyst believes the data show the validation of the therapeutic efficacy of tipifarnib and better clinical efficacy than current standards of care. "Although the market potential could seem minor, we are very encouraged tipifarnib represents a suitable and the first targeted therapy for HRAS high mutant HNSCC, and should open doors to initial tumor indications," writes Pantginis. He reiterates a Buy rating on Kura Oncology with a $31 price target.
08/01/18
HCWC
08/01/18
INITIATION
Target $31
HCWC
Buy
Kura Oncology initiated with a Buy at H.C. Wainwright
H.C. Wainwright analyst Joseph Pantginis started Kura Oncology with a Buy rating and $31 price target. The shares currently do not reflect the overall opportunity for tipifarnib, which is about to enter a pivotal program in head and neck squamous cell carcinoma patients as well as several other indications, which could lead to a broad label for the drug, Pantginis tells investors in a research note.
02/16/18
OPCO
02/16/18
NO CHANGE
Target $30
OPCO
Outperform
Kura Oncology price target raised to $30 from $17.50 at Oppenheimer
Oppenheimer analyst Leah Rush Cann raised her price target for Kura Oncology to $30 citing the positive updated preliminary results from the company's Phase II study of tipifarnib in patients with HRAS mutant head and neck squamous cell carcinoma. The analyst increased her estimated revenue in 2020-2022 by 66.7% per year. She keeps an Outperform rating on Kura Oncology.

TODAY'S FREE FLY STORIES

NUAN

Nuance

$16.27

-0.61 (-3.61%)

16:48
11/19/18
11/19
16:48
11/19/18
16:48
Hot Stocks
Nuance trades higher after quarterly report, plans to spin off Nuance Auto »

Shares of Nuance…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Nov

ORPN

Bio Blast Pharma

$1.19

-0.02 (-1.65%)

16:48
11/19/18
11/19
16:48
11/19/18
16:48
Conference/Events
Bio Blast Pharma to host conference call »

Conference call to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PSTG

Pure Storage

$17.56

-1.56 (-8.16%)

16:48
11/19/18
11/19
16:48
11/19/18
16:48
Hot Stocks
Pure Storage up 6.4% after Q3 results beat estimates, FY19 guidance raised »

In after-hours trading,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Nov

  • 26

    Nov

ORPN

Bio Blast Pharma

$1.19

-0.02 (-1.65%)

16:45
11/19/18
11/19
16:45
11/19/18
16:45
Hot Stocks
Breaking Hot Stocks news story on Bio Blast Pharma »

Bio Blast Pharma trading…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ADT

ADT Inc.

$7.68

-0.39 (-4.83%)

16:43
11/19/18
11/19
16:43
11/19/18
16:43
Initiation
ADT Inc. initiated  »

ADT Inc initiated with an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Nov

ARMK

Aramark

$35.81

-1.045 (-2.84%)

16:42
11/19/18
11/19
16:42
11/19/18
16:42
Initiation
Aramark initiated  »

Aramark initiated with an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CTAS

Cintas

$179.63

-3.47 (-1.90%)

16:41
11/19/18
11/19
16:41
11/19/18
16:41
Initiation
Cintas initiated  »

Cintas initiated with an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BECN

Beacon Roofing

$27.74

0.12 (0.43%)

16:40
11/19/18
11/19
16:40
11/19/18
16:40
Earnings
Beacon Roofing sees FY19 adjusted EPS $2.90-$3.35, consensus $3.79 »

Sees FY19 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Nov

  • 13

    Dec

SERV

ServiceMaster

$41.84

-0.58 (-1.37%)

16:40
11/19/18
11/19
16:40
11/19/18
16:40
Initiation
ServiceMaster initiated  »

ServiceMaster initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Dec

EEX

Emerald Expositions Events

$10.92

-0.63 (-5.45%)

16:39
11/19/18
11/19
16:39
11/19/18
16:39
Initiation
Emerald Expositions Events initiated  »

Emerald Expositions…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PBIP

Prudential Bancorp

$17.32

-0.03 (-0.17%)

16:38
11/19/18
11/19
16:38
11/19/18
16:38
Hot Stocks
Prudential Bancorp announces third stock repurchase program for 900,000 shares »

Prudential Bancorp…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

POST

Post Holdings

$91.74

-4.31 (-4.49%)

16:37
11/19/18
11/19
16:37
11/19/18
16:37
Syndicate
Post Holdings announces termination of convertible preferred stock offering »

Post Holdings announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FULT

Fulton Financial

$16.89

-0.06 (-0.35%)

16:36
11/19/18
11/19
16:36
11/19/18
16:36
Hot Stocks
Fulton Financial announces special cash dividend of four cents per share »

Fulton Financial …

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NFG

National Fuel

$53.79

0.755 (1.42%)

16:35
11/19/18
11/19
16:35
11/19/18
16:35
Hot Stocks
National Fuel CIO Wegrzyn to retire »

National Fuel Gas Company…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LB

L Brands

$34.53

-0.75 (-2.13%)

16:35
11/19/18
11/19
16:35
11/19/18
16:35
Hot Stocks
L Brands names John Mehas as CEO of Victoria's Secret Lingerie unit »

The company also…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Nov

XOMA

Xoma

$14.22

-0.045 (-0.32%)

16:35
11/19/18
11/19
16:35
11/19/18
16:35
Syndicate
Xoma commences rights offering to raise approximately $20M »

XOMA announced it has…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DNLI

Denali Therapeutics

$18.18

-1.05 (-5.46%)

, SNY

Sanofi

$44.92

-0.19 (-0.42%)

16:34
11/19/18
11/19
16:34
11/19/18
16:34
Hot Stocks
Denali Therapeutics reports 'positive' results from Phase 1 DNL747 study »

Denali Therapeutics…

DNLI

Denali Therapeutics

$18.18

-1.05 (-5.46%)

SNY

Sanofi

$44.92

-0.19 (-0.42%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Dec

  • 28

    Jan

  • 11

    Mar

  • 22

    Mar

  • 28

    Apr

LB

L Brands

$34.53

-0.75 (-2.13%)

16:34
11/19/18
11/19
16:34
11/19/18
16:34
Earnings
L Brands raises FY18 EPS view to $2.60-$2.80 from $2.45-$2.70, consensus $2.63 »

CEO Leslie Wexner states:…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Nov

PGNX

Progenics

$5.20

-0.16 (-2.99%)

16:34
11/19/18
11/19
16:34
11/19/18
16:34
Hot Stocks
Progenics announces presentation of updated data for Azedra »

Progenics Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Nov

LB

L Brands

$34.53

-0.75 (-2.13%)

16:34
11/19/18
11/19
16:34
11/19/18
16:34
Earnings
Breaking Earnings news story on L Brands »

L Brands sees Q4 EPS…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Nov

HGV

Hilton Grand Vacations

$29.52

-0.09 (-0.30%)

16:33
11/19/18
11/19
16:33
11/19/18
16:33
Hot Stocks
Hilton Grand Vacations names Gordon Gurnik as COO »

Hilton Grand Vacations…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Dec

LB

L Brands

$34.53

-0.75 (-2.13%)

16:33
11/19/18
11/19
16:33
11/19/18
16:33
Hot Stocks
Breaking Hot Stocks news story on L Brands »

L Brands reports Q3 SSS…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Nov

LB

L Brands

$34.53

-0.75 (-2.13%)

16:32
11/19/18
11/19
16:32
11/19/18
16:32
Hot Stocks
L Brands to cut annual dividend to $1.20 from $2.40 »

After extensive review,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Nov

T

AT&T

$30.34

0.04 (0.13%)

16:32
11/19/18
11/19
16:32
11/19/18
16:32
Periodicals
CNN abandons WH suit after Acosta's press pass restored, WP says »

CNN has withdrawn its…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Nov

  • 03

    Dec

YUM

Yum! Brands

$88.15

-0.77 (-0.87%)

, TGT

Target

$77.77

-1.9 (-2.38%)

16:31
11/19/18
11/19
16:31
11/19/18
16:31
Hot Stocks
Yum! Brands names Brian Cornell as non-executive Chairman of Board »

Yum! Brands (YUM)…

YUM

Yum! Brands

$88.15

-0.77 (-0.87%)

TGT

Target

$77.77

-1.9 (-2.38%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Nov

  • 03

    Mar

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.